Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
Sponsor: Bausch Health Americas, Inc.
Summary
This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects, with active, mild to moderate ulcerative colitis (UC). Subjects will be permitted to continue taking background oral or rectal 5-aminosalicylate (5-ASA) products.
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets n Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
Key Details
Gender
All
Age Range
5 Years - 17 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2023-09-29
Completion Date
2027-06
Last Updated
2025-09-16
Healthy Volunteers
No
Conditions
Interventions
Low Dose Budesonide
3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.
High Dose Budesonide
6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.
Placebo
Matching placebo once daily.
Locations (4)
Bausch Health Site 008
Garden Grove, California, United States
Bausch Health Site 003
Indianapolis, Indiana, United States
Bausch Health Site 006
The Bronx, New York, United States
Bausch Health Site 010
Greenville, North Carolina, United States